CELCC 2020 - Virtual Event

27. 11. 2020
Opening session

Opening remarks

Luboš Petruželka (CZE)

27. 11. 2020
Opening session

Statistics in clinical trials and medical research

Ondřej Májek (CZE)   

27. 11. 2020
Session I

Management of small lung nodules

Helmut Prosch (AUT)

27. 11. 2020
Session I

Circulating biomarkers in early detection and treatment of lung cancer

Filip Janků (USA)   

27. 11. 2020
Session I

Pilot screening project in the Czech Republic

Jiří Votruba (CZE)   

27. 11. 2020
Session I

Experience with screening in Croatia

Ante Marušić (CRO)   

27. 11. 2020
Session I

HUNCHEST screening in Hungary

Anna Kerpel-Fronius (HUN)   

27. 11. 2020
Session I

Panel discussion

27. 11. 2020
Satellite symposium I

ROCHE

27. 11. 2020
Session II

Artificial intelligence in imaging

Lukáš Lambert (CZE)   

27. 11. 2020
Session II

New technologies in imaging

David Zogala (CZE)   

27. 11. 2020
Session II

Next generation sequencing in diagnosis: indications and utilization rate

Jószef Tímár (HUN)   

27. 11. 2020
Session II

Predictive biomarkers for the treatment of NSCLC

Kristýna Němejcová (CZE)   

27. 11. 2020
Special session

Conquering lung cancer in Central Europe

Jean Klastersky (BEL)   

28. 11. 2020
Session III

Minimally invasive surgery

Mir Alireza Hoda (AUT)   

28. 11. 2020
Session III

Proton radiotherapy in early stage of lung cancer treatment

Jiří Kubeš (CZE)   

28. 11. 2020
Session III

Stereotactic radiotherapy of NSCLC

Jakub Cvek (CZE)   

28. 11. 2020
Session III

The role of radiotherapy fractionation

Karin Dieckmann (AUT)   

28. 11. 2020
Session IV

Care of patients with Non-Small-Cell lung cancer stage III – the Central European real-world experience – final analysis

Milada Zemanová (CZE)   

28. 11. 2020
Session IV

Patient case study: tratment variability in N2 positive stage III NSCLC

Daniel Krejčí (CZE)   

28. 11. 2020
Session IV

Adjuvant therapy of resected NSCLC

Robert Pirker (AUT)   

28. 11. 2020
Session IV

Induction therapy followed by surgery in NSCLC

Renata Soumarová (CZE)   

28. 11. 2020
Session IV

Definitive chemoradiotherapy

Jacek Jassem, Poland   

28. 11. 2020
Session IV

Panel discussion

28. 11. 2020
Satellite symposium II

Bristol Myers Squibb

28. 11. 2020
Session V

Immunotherapy beyond checkpoint inhibitors

Radek Špíšek (CZE)   

28. 11. 2020
Session V

Atezolizumab in metastatic lung cancer – current evidence

Libor Havel (CZE)   

28. 11. 2020
Session V

Durvalumab (metastatic non small cell lung cancer)

Gyula Ostoros (HUN)   

28. 11. 2020
Session V

Nivolumab

Helena Linardou (GRE)   

28. 11. 2020
Session V

Pembrolizumab

Luboš Petruželka (CZE)   

28. 11. 2020
Session V

Panel discussion

28. 11. 2020
Session VI

EGFR mutation-positive NSCLC: recent advances

Krisztina Bogos (HUN)   

28. 11. 2020
Session VI

Liquid biopsy for disease monitoring

Martin Filipits (AUT)   

28. 11. 2020
Session VI

Targeted therapies of mutation-positive NSCLC

Nir Peled (ISR)   

29. 11. 2020
Session VII

Agressive pulmonary adenocarcinoma with new FGFR translocation and cMET mutation not responsive to crizotinib and nintedanib treatment – a case report

Martin Svatoň (CZE)   

29. 11. 2020
Session VII

Multidisciplinary management in stage III NSCLC

Thomas Klikovits (AUT)   

29. 11. 2020
Session VII

Successful multivariate treatment of stage IV EGFR Exon-19 mutant pulmonary adenocarcinoma

Gabriella Gálffy (HUN)   

29. 11. 2020
Session VIII

Small cell lung cancer: treatment advances

Nevena Sečen (SRB)   

29. 11. 2020
Session VIII

Malignant pleural mesothelioma: treatment advances

Marko Jakopović (CRO)   

29. 11. 2020
Session VIII (Posters)

Definitive chemoradiotherapy of locally advanced Non-Small Cell Lung Cancer (LA-NSCLC) with IGRT technique using tomotherapy HD – updated analysis

Stanislav Hloušek et al (CZE)   

29. 11. 2020
Session VIII (Posters)

The role of serum tumour markers in the detection of malignant lung tumours

Martin Skála et al (CZE)   

29. 11. 2020
Session VIII (Posters)

Impact of concomitant medication administered at the time of initiation of the outcome of nivolumab therapy in Non-Small Cell Lung Cancer

Martin Svatoň et al (CZE)   

29. 11. 2020
Session VIII (Posters)

Examination of the immune cells profile of NSCLC patients indicated for inhibitory checkpoint immunotherapy

Jan Špaček et al (CZE)   

29. 11. 2020
CELCC 2020 Farewell:

Closing Remarks

Lubos Petruželka (CZE)
Robert Pirker (AUT)
Gyula Ostoros (HUN)